Skip to content
TheBrief.Health

Living with Type 2 Diabetes

Stories from people navigating Type 2 Diabetes — diagnosis, treatment, caregiving, and the ordinary days in between.

23 stories

A weekly medication organizer beside an insulin pen and glucose meter on a clinical desk.

Endocrinology & Metabolism

Type 2 Diabetes Gains a Once-Weekly Insulin Option

FDA approval of insulin efsitora alfa-gobe creates a weekly basal insulin option for adults with type 2 diabetes, making treatment burden, hypoglycemia risk and follow-up capacity central to selection.

Rayan Salih · November 2, 2026 · 7 min

Three medication containers beside a heart and kidney model on a clinical desk

Cardiology

SGLT2 Inhibitors, Finerenone and Semaglutide Differ

A meta-analysis of 10 randomized datasets and 37,923 participants found distinct cardiorenal outcome patterns across SGLT2 inhibitors, finerenone and semaglutide, arguing against treating them as interchangeable.

Rayan Salih · 7 min read

Questions clinicians ask

What cardiovascular benefits are associated with GLP-1 receptor agonists in adults with type 2 diabetes?
The briefs indicate that several GLP-1 receptor agonists improve major cardiovascular outcomes in people with type 2 diabetes, particularly those with elevated cardiovascular risk. Access barriers may limit realization of these benefits in routine metabolic care.
What happens to weight after patients with type 2 diabetes stop GLP-1 receptor agonist therapy?
Real-world evidence described in the briefs shows weight regain after GLP-1 receptor agonist discontinuation, although the average regain was modest. Outcomes may vary by treatment duration, indication, and post-discontinuation lifestyle or medication changes.
Do healthy lifestyle behaviors reduce cardiovascular risk in type 2 diabetes among patients using GLP-1 medications?
Healthy diet, physical activity, and smoking cessation are associated with lower cardiovascular risk in people with type 2 diabetes. This association remains evident regardless of GLP-1 medication use, supporting lifestyle behaviors as complementary rather than redundant.
Are GLP-1 receptor agonists associated with worsening mental health in patients with type 2 diabetes?
The covered evidence suggests that some GLP-1 receptor agonists may be associated with a lower risk of worsening mental health rather than an increased risk. The finding should not be generalized to every agent or psychiatric outcome because effects may differ across medications and patient populations.

Other conditions

One story a day

The story of the day, in your inbox

One health journey each morning — no advice, no alarm, just company for the road.